Aktuelle Therapiekonzepte beim Hodgkin-Lymphom

Durch die Einführung neuer Therapien konnte die Erstlinientherapie deeskaliert und die Prognose für Patienten mit Hodgkin-Lymphom (HL) entscheidend verbessert werden. Dieser Beitrag gibt einen Überblick über die aktuellen Therapiekonzepte beim HL und beleuchtet die jüngsten Entwicklungen.

• Literatur

• 1 Borchmann P, Goergen H, Kobe C. et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018; 390: 2790-2802
• 2 von Tresckow B, Plütschow A, Fuchs M. et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-913
• 3 Engert A, Plütschow A, Eich HT. et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010; 363: 640-652
• 4 Chen R, Zinzani PL, Fanale MA. et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 2017; 35: 2125-2132
• 5 Gopal AK, Chen R, Smith SE. et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125: 1236-1243
• 6 Sasse S, Bröckelmann PJ, Goergen H. et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017; 35: 1999-2007
• 7 Raemaekers JMM, André MPE, Federico M. et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188-1194
• 8 Engert A, Diehl V, Franklin J. et al. Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin’s Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. J Clin Oncol 2009; 27: 4548-4554
• 9 Engert A, Goergen H, Markova J. et al. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma. HemaSphere 2017; 1: e5
• 10 Skoetz N, Trelle S, Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943-952
• 11 Morschhauser F, Brice P, Fermé C. et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-5987
• 12 Moskowitz CH, Nademanee A, Masszi T. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853-1362
• 13 Younes A, Santoro A, Shipp M. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283-1294
• 14 Santoro A, Bredenfeld H, Devizzi L. et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-2619
• 15 Moskowitz AJ, Hamlin P, Perales MA. et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456-460
• 16 Wongso D, Fuchs M, Plutschow A. et al. Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group. J Clin Oncol 2013; 31: 2819-2824
• 17 Böll B, Goergen H, Behringer K. et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189-2192
• 18 Schulz H, Rehwald U, Morschhauser F. et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109-111
• 19 Fanale MA, Lai CM, McLaughlin P. et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (NLPHL) Patients Treated with R-CHOP. Blood 2010; 116: 2812